M.X. Pham

TL;DR: Among selected patients who had received a cardiac transplant more than 6 months previously and who were at a low risk for rejection, a strategy of monitoring for rejection that involved gene-expression profiling, as compared with routine biopsy was not associated with an increased risk of serious adverse outcomes and resulted in the performance of significantly fewer biopsies.

TL;DR: The IMAGE study is the first randomized, controlled comparison of two rejection surveillance strategies measuring outcomes in heart transplant recipients who are beyond their first year post-transplant.

TL;DR: Medical records of all cardiac transplants performed at Stanford were reviewed and long‐term survival is expected to occur at much higher rates in the future due to major advances in the field over the past decade.

TL;DR: Early after cardiac transplantation, rapamycin therapy is associated with improved coronary artery physiology involving both the epicardial vessel and the microvasculature and was an independent predictor of CFR and FFR at 1 year after transplantation.

TL;DR: The variability of a heart recipient’s gene expression profiling test scores over time may provide prognostic utility and is independent of the probability of acute cellular rejection at the time of testing that is rendered from a single ordinal gene-expression profiling test score.